Q-omics provides the consensus-scored ANKRD65 profile across patient tissues and cancer cell-line models. ANKRD65 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ANKRD65 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ANKRD65 RNA expression shows 16,220 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight LUAD, KIRC, and CCRCC as cancer lineages where ANKRD65 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD65 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD65 survival associations across molecular data types. ANKRD65 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD65 RNA expression–survival associations across cancer types. High ANKRD65 expression shows unfavorable associations in LGG, but favorable associations in LUAD, UVM, HNSC, KICH and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ANKRD65 RNA expression.
This table summarizes ANKRD65 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD65. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD65 shows lower tumor expression in KIRC, KICH, KIRP and BRCA and higher tumor expression in LIHC and BLCA. The KIRC box plot shows higher ANKRD65 RNA expression in normal versus tumor tissue (log2 FC = −0.874, t-test p < 0.001).
This table shows molecular features associated with ANKRD65 in patient tissues and cancer cell lines. In patient samples, ANKRD65 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD65 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
